Effects of concomitant use of doxifluridine, radiotherapy and immunotherapy in patients with advanced cervical cancer

Yamamoto,Kaichiro; Noda,Kiichiro; Hatae,Masayuki; Kudo,Takafumi; Hasegawa,Kazuo; Nishimura,Ryuichiro; Honjo,Hideo; Yajima,Akira; Sato,Shinji; Mizutani,Katsumi; Yakushiji,Michiaki; Terashima,Yoshiteru; Ochiai,Kazunori; Sasaki,Hiroshi; Ozaki,Masami

doi:10.3892/or.8.2.273

Effects of concomitant use of doxifluridine, radiotherapy and immunotherapy in patients with advanced cervical cancer

Authors:
- Kaichiro Yamamoto
- Kiichiro Noda
- Masayuki Hatae
- Takafumi Kudo
- Kazuo Hasegawa
- Ryuichiro Nishimura
- Hideo Honjo
- Akira Yajima
- Shinji Sato
- Katsumi Mizutani
- Michiaki Yakushiji
- Yoshiteru Terashima
- Kazunori Ochiai
- Hiroshi Sasaki
- Masami Ozaki
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Sakai Hospital, Kinki University School of Medicine, Sakai, Osaka 590-0132, Japan
Published online on: March 1, 2001 https://doi.org/10.3892/or.8.2.273
Pages: 273-277

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Clinical effects of doxifluridine (group A, 600 mg/body/day; group B, 800 mg/body/day) combined with radiotherapy and immunotherapy were evaluated in patients with advanced cancer of the uterine cervix. Response rates were 84.2% (16/19 patients) in group A and 100% (18/18 patients) in group B, respectively (p=0.230). There was no significant difference in adverse reaction incidence between the methods but significantly higher grade adverse reaction were observed in group B than in group A (p=0.048). Time to progression (TTP) was longer in group B than in group A (p=0.081). The optimal 5'-DFUR dose was 800 mg/body (group B), by which higher grade adverse reactions were fully controlled and TTP was prolonged.